Hot Investor Mandate 1: Global Pharma Makes Equity Investments In Oncology, Cardio and Ophthalmology

10 Dec

A large pharma company based in Hong Kong makes equity investments and also in-licenses assets for development. Typical equity investments range from $2-3M per deal. The firm has partnered with companies in Japan, the USA and Europe, and is currently looking for new opportunities globally.

Currently the firm is seeking therapeutics in oncology, supportive care, cardiovascular, and ophthalmology. The firm focuses on small molecule, biologics, biosimilars, and repurposed and reformulated drugs. The firm typically in-licenses assets that have completed IND enabling studies, while it can consider from pre-clinical to on-market assets.

The firm is seeking innovative assets that address large unmet medical need. The firm generally seeks development and/or commercialization rights in China and Southeast Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: